P. Gebrehiwet

Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States

P. Gebrehiwet, James Jackson, Lucy Hargreaves, Sophie Barlow et autres

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive, genetic heart disease characterized by hypercontractility and hypertrophy. As treatment options evolve, characterizing the existing healthcare needs and health-related quality of life (HRQoL) for patients with HCM is important. Data were derived from the Adelphi …

Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States

P. Gebrehiwet, James Jackson, Lucy Hargreaves, Sophie Barlow et autres

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive, genetic heart disease characterized by hypercontractility and hypertrophy. As treatment options evolve, characterizing the existing healthcare needs and health-related quality of life (HRQoL) for patients with HCM is important. Data were derived from the Adelphi …

Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States

P. Gebrehiwet, James Jackson, Lucy Hargreaves, Sophie Barlow et autres

BACKGROUND AND AIMS: Hypertrophic cardiomyopathy (HCM) is a chronic, progressive, genetic heart disease characterized by hypercontractility and hypertrophy. As treatment options evolve, characterizing the existing healthcare needs and health-related quality of life (HRQoL) for patients with HCM is important. METHODS: Data were …

us, gb (code pays fourni par la source)

Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States

P. Gebrehiwet, James Jackson, Lucy Hargreaves, Sophie Barlow et autres

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive, genetic heart disease characterized by hypercontractility and hypertrophy. As treatment options evolve, characterizing the existing healthcare needs and health-related quality of life (HRQoL) for patients with HCM is important. Data were derived from the Adelphi …

EPH184 A U.S. BURDEN OF DISEASE PROJECTION MODEL FOR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, 2027-2035

P. Gebrehiwet, J Ortendahl, Matthew Sussman, Laura Cianciolo et autres

us (code pays fourni par la source)

Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023

Michael Butzner, Andrew K. ElHabr, Kian Farajkhah, Jagpreet Chhatwal et autres

BACKGROUND: Data on the contemporary prevalence of hypertrophic cardiomyopathy (HCM) in the United States are limited, and information on the epidemiology by disease characteristics and patient demographics is lacking. OBJECTIVES: This study aimed to estimate the prevalence and incidence of HCM in …

us (code pays fourni par la source)

Association Of Sociodemographic Characteristics And Healthcare Costs In Patients With Nonobstructive Cardiomyopathy

Nosheen Reza, Michael Butzner, Kirti Batra, Qiana Amos et autres

us (code pays fourni par la source)

CO137 Impact of Disease Progression on Healthcare Resource Utilization and Quality of Life in Patients With Hypertrophic Cardiomyopathy: A Real-World Cross-Sectional Survey

P. Gebrehiwet, J. Mark Jackson, Louise Hancock, Sophie Barlow et autres

us, gb (code pays fourni par la source)

P3 Long Term Healthcare Costs and Utilization Among Patients with Non Obstructive Hypertrophic Cardiomyopathy

Nosheen Reza, Kirti Batra, Qiana Amos, Ami Buikema et autres

us (code pays fourni par la source)

CO78 Clinical and Economic Burden of Non-Obstructive Hypertrophic Cardiomyopathy: A Literature Review

P. Gebrehiwet, Laura Cianciolo, Jesse D. Ortendahl, Matthew Sussman et autres

us (code pays fourni par la source)

CO186 Assessing Differences in Clinical Burden Across Payers for Non-Obstructive Hypertrophic Cardiomyopathy

Nosheen Reza, Kirti Batra, Qiana Amos, Ami Buikema et autres

us (code pays fourni par la source)

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial

Stacy A. Rudnicki, P. Gebrehiwet, Stuart Kupfer, Fady I. Malik et autres

Objectives To describe participant, site personnel (SP) and sponsor perspectives regarding their experiences with a decentralized clinical trial (DCT).Methods COURAGE-ALS was a 48-week, double-blind, randomized, phase III, hybrid DCT of reldesemtiv versus placebo for ALS. Fifty participants completed semi-structured interviews at Week …

us (code pays fourni par la source)